NB003
NB003 Phase 1
Ningbo Newbay Technology Development · Phase 1 · Completed · Enrollment 258
| Arm | Population | Dose | Estimand | Comparator | Efficacy |
|---|---|---|---|---|---|
| NB003, 2L to 4L or later | GIST 2L to 4L or later (n = 158) | not stated in source | Single arm | n/r | objective response rate: 28.5%, data as of March 2025median progression-free survival: 9.2 months, data as of March 2025 |
| NB003, 3L subgroup | GIST 3L (n not stated in source) | not stated in source | Single arm | n/r | objective response rate: 46.7%, data as of March 2025median progression-free survival: 13.7 months, data as of March 2025 |